The aminocarnitine derivative teglicar (R)-N-(tetradecylcarbamoyl)-aminocarnitine (ST1326), a selective and reversible inhibitor of CPT1A originally used as a drug candidate for diabetes therapy [32,33], also plays a central role in the therapy of certain cancers. This evidence concerns the gene CPT1A and diabetes mellitus.